ClinicalTrials.gg
Active, not recruitingNCT06153108Updated Jun 29, 2026

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

An observational study in Inclusion Body Myositis, sponsored by University of Kansas Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by University of Kansas Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Planned enrollment
9th of 10
20 · median 59
Started
2023
with 1 other
Observational
10 of 37
3 open now
Registered
32nd of 37
by date
Lead sponsor
4 of 37
University of Kansas Medical Center

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2023, is one of 10 observational ones, and was the 32nd registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 45 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

Inclusion-Body Myositis (IBM) results in weakness and the deterioration of distal arm muscles, the symptoms of which are currently assessed through expert examination at clinical visits. Such in-clinic assessments are time-consuming, subjective, of limited sensitivity, and only provide a snapshot of a patient's disease. In this project, the investigators will conduct clinical validation of monitoring digital biomarkers of upper limb function during activities of daily living using a wearable sensor platform that enables frequent, at-home monitoring of upper limb function health in IBM and could be incorporated into IBM trials.

03

Conditions studied

  • Inclusion Body Myositis

Keywords

  • Biomarker
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Subjects with diagnosed inclusion body myositis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM.
  2. Able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Unwillingness to follow study procedures.
  2. Participation in an drug research study within the past 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Interventions

  • DevicePAMSys pendant PAMSys wrist sensors

    The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz

06

What researchers measure

Primary outcomes

  1. Investigate validity of PAMSys wrist sensor and pendant sensor as monitoring biomarker of upper and lower limb function and physical activity, including leg function, change in IBM patients.

    will investigate if sensor-derived parameters measured by the PAMSys wrist sensors and pendant sensor can quantify disease severity and track subtle changes in upper and lower limb health and ambulation over time.

    Time frame: Baseline, Month 6, Month 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Feb 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 1, 2023
StartActual
Nov 16, 2023
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153108
Collaborators
BioSensics
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Nov 16, 2023
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Mazen Dimachkie, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion